[前列腺癌骨转移患者：双膦酸盐能有所帮助吗？] - Suppr

Suppr

超能文献

[Patients with prostate cancer bone metastases: can bisphosphonates help?].

作者信息

Krabbe Laura-Maria

机构信息

UroEvidence, Nestorstraße 8-9 (1. Hof), 10709, Berlin, Deutschland.

出版信息

Urologe A. 2019 Mar;58(3):314-318. doi: 10.1007/s00120-019-0881-x.

DOI:10.1007/s00120-019-0881-x

PMID:30767031

Abstract

摘要

相似文献

[Patients with prostate cancer bone metastases: can bisphosphonates help?].

Urologe A. 2019 Mar;58(3):314-318. doi: 10.1007/s00120-019-0881-x.

[The role of bisphosphonate in the treatment of bone metastases from prostate cancer].

Tunis Med. 2012 Jul;90(7):507-11.

Words of Wisdom. Re: Randomized Controlled Trial of Early Zoledronic Acid in Men with Castration-sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance).

Eur Urol. 2016 Apr;69(4):754-5. doi: 10.1016/j.eururo.2016.01.019. Epub 2016 Feb 18.

The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel.

Clin Genitourin Cancer. 2006 Mar;4(4):257-62. doi: 10.3816/CGC.2006.n.004.

[The effect of bisphosphonates on bone metastasis of hormone-refractory prostate cancer].

Hinyokika Kiyo. 2006 Jun;52(6):491-4.

The if's, and's, or but's regarding bisphosphonates for prostate cancer.

J Natl Cancer Inst. 2007 May 16;99(10):744-5. doi: 10.1093/jnci/djk194.

Bone complications: an increasing risk in patients with prostate cancer.

J Support Oncol. 2007 Feb;5(2):88-9.

What are the efficacy and safety of bisphosphonates and RANK-ligand-inhibitors for men with prostate cancer and bone metastases? - A Cochrane Review summary with commentary.

J Musculoskelet Neuronal Interact. 2021 Dec 1;21(4):451-454.

Is time to first skeletal-related event the best primary end point in the assessment of bisphosphonate efficacy in patients with castration-sensitive prostate cancer?

J Clin Oncol. 2014 Nov 10;32(32):3684-5. doi: 10.1200/JCO.2014.56.2017. Epub 2014 Sep 15.

Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial.

J Urol. 2013 Jan;189(1 Suppl):S51-7; discussion S57-8. doi: 10.1016/j.juro.2012.11.022.

本文引用的文献

Bisphosphonates for advanced prostate cancer.

Cochrane Database Syst Rev. 2017 Dec 26;12(12):CD006250. doi: 10.1002/14651858.CD006250.pub2.

Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline.

Clin Oncol (R Coll Radiol). 2017 Jun;29(6):348-355. doi: 10.1016/j.clon.2017.01.007. Epub 2017 Feb 4.

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.

Eur Urol. 2017 Apr;71(4):630-642. doi: 10.1016/j.eururo.2016.08.002. Epub 2016 Aug 31.

TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.

Health Technol Assess. 2016 Jul;20(53):1-288. doi: 10.3310/hta20530.

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.

Lancet. 2016 Mar 19;387(10024):1163-77. doi: 10.1016/S0140-6736(15)01037-5. Epub 2015 Dec 21.

Eur Urol. 2015 Jul;68(1):42-50. doi: 10.1016/j.eururo.2014.10.001. Epub 2014 Oct 29.

Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).

J Clin Oncol. 2014 Apr 10;32(11):1143-50. doi: 10.1200/JCO.2013.51.6500. Epub 2014 Mar 3.

Effects of bone-targeted agents on cancer progression and mortality.

J Natl Cancer Inst. 2012 Jul 18;104(14):1059-67. doi: 10.1093/jnci/djs263. Epub 2012 Jul 2.

Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).

Eur J Cancer. 2012 Nov;48(16):2993-3000. doi: 10.1016/j.ejca.2012.05.014. Epub 2012 Jun 6.

Zoledronic Acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer.

Urology. 2010 Nov;76(5):1175-81. doi: 10.1016/j.urology.2010.05.026.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验